Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses treatment approaches for transplant-eligible and transplant-ineligible myeloma patients and the benefit of these combination therapies. Dr Ramasamy discusses the option of quadruplet therapy with daratumumab, bortezomib, thalidomide, and dexamethasone (D-VTd) for transplant-eligible patients, and lenalidomide plus dexamethasone or bortezomib-based regimens for transplant-ineligible patients. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.